
Dassault Systèmes and Patrick Jouin Unveil 'Ta.Tamu,' Their Latest Collaboration Redefining Traditional Design
PARIS--(BUSINESS WIRE)-- Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and the French designer Patrick Jouin today unveiled 'Ta.Tamu,' a lightweight, 3D-printed and functional chair, co-created using the 3DEXPERIENCE platform on the cloud. Ta.Tamu serves as a proof of concept for emerging, generative design processes that combine AI-powered virtual twins and the frugal use of materials to drive the generative economy.
Ta.Tamu is the result of a four-year dialogue between Patrick Jouin's intuitive design approach and Dassault Systèmes' 3DEXPERIENCE platform. Designers and engineers redefined how a chair could be conceived — challenging traditional design methods, pushing formal and structural limits, and inventing new ways to minimize matter.
Developed through enhanced ideation and concept development, and a life cycle assessment integrated early in the process, Ta.Tamu's pioneering aesthetics were inspired by biomimicry and the structural logic of the human body, such as bone density and joint articulation. The light yet robust lattice structure weighs just 8.6 pounds (3.9 kg), can support 220 pounds (100 kg), and can be 3D printed in a flat, folded position without needing assembly.
'Nature uses only the energy and materials it needs. We wanted to apply this very simple philosophy to the development of Ta.Tamu. With the help of new collaborative technologies of Dassault Systèmes, we are now able to come up with new ideas and make them possible, creating more efficiently while producing less waste, right from the design process,' said Jouin.
Collaborating around an AI-powered virtual twin, design teams modeled and simulated the behavior of complex assembled components, using topological optimization to refine every joint, unfolding articulation, and zone of pressure and support. At each stage, the design evolved in real time through close interaction with the 3DEXPERIENCE platform, with changes updated and visible in the virtual twin. Teams modified the chair's geometry while balancing its aesthetics, resulting in an optimal design where gesture, function, and structure converge in a chair that weighs 75% less than it would have weighed at full density.
'To improve the world we live in, we have to change the way we produce, design and use materials. Ta.Tamu represents a call to action for industry to embrace a generative economy instead of continuing to create without limits,' said Anne Asensio, Vice President Design Experience, Dassault Systèmes. 'Ta.Tamu was created with the technology used to innovate sustainably in industrial contexts. As a science-based company, we want to create value for society in every aspect of people's lives through our 3DEXPERIENCE platform. Design processes integrating modeling and simulation from the start lead to innovations that improve real life.'
###
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes' 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com
About Patrick Jouin
Patrick Jouin is a French designer and a graduate of ENSCI–Les Ateliers. In 1999, he founded his industrial design studio, Patrick Jouin iD. A pioneer in the use of 3D printing for furniture design, he created the Solid collection in 2004, the first series of furniture pieces produced directly from digital files, without molds or assembly. This milestone marked the beginning of an in-depth exploration of new ways to design and manufacture, rethinking forms, gestures, and structures in light of emerging technologies.
Through objects such as One Shot, Bloom, and the monolithic bench at the Palais de Tokyo, Patrick Jouin has revealed the ability of these tools to generate intuitive, lightweight, and sometimes otherwise unattainable forms. Since 2019, he has been engaged in an experimental collaboration with Anne Asensio and the teams at Dassault Systèmes, exploring generative design, folding, and deployability.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces filing for insolvency 1 and requesting to be placed in receivership 2 to the Versailles Economic Affairs Court 3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening. Insolvency filing and request to be placed in receivership On June 20, 2025, CARMAT announced in a press release being at risk of insolvency as early as the end of June 2025 unless managing before then, to secure additional cash of at least €3.5 million. Despite its continued efforts, the Company has not managed at this stage, to secure neither additional cash nor new financing. Given this, the Company will today file for insolvency and request to be placed in receivership to the Versailles Economic Affairs Court ('the Court'). The Court will rule on this request, following a hearing expected in the coming days. As a reminder, according to its current business plan and assuming 'business as usual' situation, the Company estimates its funding requirements over the next 12 months at approximately €35 million, including approximately €20 million by the end of December 2025. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Pending the Court's decision, CARMAT has asked Euronext to suspend the trading of its shares starting on June 30, 2025, before the stock market opens. The Company anticipates this suspension to be lifted once the Court's decision has been rendered and communicated to the market. Next steps Pending the Court's decision, CARMATS's operations carry-on and the Company continues to actively explore all options to ensure the continuation of its business activities. The Company believes that the opening of a receivership procedure would be the most appropriate framework to facilitate this continuation. More generally, whatever the Court's decision, the Company will endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will be issued regularly as the Company's situation evolves and the proceedings progress. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).


Business Wire
an hour ago
- Business Wire
cippe to Organize Oil, Gas and Chemical Exhibition in Xinjiang, Along With Forum on Deep and Ultra-Deep E&P
URUMQI, China--(BUSINESS WIRE)--2025 Xinjiang International Petroleum & Chemical Technology and Equipment Exhibition (cippe Xinjiang) will be held on July 18-20, 2025 at Urumqi, Xinjiang, China. cippe Xinjiang is expected to cover an exhibition space up to 40,000sqm, and gather 500+ exhibitors. Supported by China Petroleum and Chemical Industry Federation, China Petroleum & Petrochemical Equipment Industry Association, Explosion-Proof Electrical Apparatus Branch of China Electrical Equipment Industry Association, Xinjiang Uygur Autonomous Region Petroleum and Chemical Industry Association, China University of Petroleum-Beijing at Karamay, cippe Xinjiang is expected to cover an exhibition space up to 40,000sqm, and gather 500+ exhibitors. cippe is one of the world's leading brands for petroleum and petrochemical exhibitions, among them, cippe Beijing is the most well-known and has successfully held 25 editions. In this March, cippe Beijing had welcomed Gerab to showcase their seamless pipes and allied components, also the attendance of visitors from UAE, Iraq, Oman, Iran, Kuwait, Saudi Arabia, Qatar and others, including companies such as United Energy, ADNOC, Aramco Asia, Qatar Lubricants & Petrochemicals, etc. Xinjiang lies in the hinterland of the Eurasian continent and adjourns countries in central Asia, south and west Asia, functions as a key gate for China's opening up, as well as an important base for oil and gas, refining, and chemical development in China. The four major oilfields in Xinjiang, namely Xinjiang Oilfield, Tarim Oilfield, Northwest Oilfield, and Tuha Oilfield, among which, there are two listed as the top 10 oilfields in China. cippe Xinjiang, which debuted in 2023, is an event to bring together oil, gas and chemical industry players in Xinjiang and Northwest China. CNOOC Energy Technology & Services (CenerTech), CNPC Xibu Drilling, XCMG, AECC GT, Anton, Dongfang Xianke, Haimo, Shenhua, Rushi, Vigor, Huaneng Cable, Shenwang Group, Yangshi Machinery, Maxwell Energy, INVT Electric, ZhongTe Vik Petroleum Machinery, Weima Pumps and others will showcase on cippe Xinjiang. Concurrently, the Third China Deep and Ultra-Deep Oil and Gas Development Forum will be held on July 18, at the conference zone of the venue, which is based on the reservoir characteristics of oilfields in Xinjiang. Academician of the CAS and CAE, management and technical personnel from science and technology departments and research institutes of CNPC, Sinopec, CNOOC, Tarim Oilfield, Huabei Oilfield, Tuha Oilfield, GWDC, Daqing Drilling, Beijing and Karamay campuses of China University of Petroleum, etc., will be invited to share.


Business Wire
9 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.